CHADDS FORD, Pa., Jan. 4, 2011 /PRNewswire/ — Endo
Pharmaceuticals (Nasdaq:
ENDP) today announced that it will present at the J.P. Morgan
29th Annual Healthcare Conference on Monday, January 10, 2011 at
1:30 p.m. PT. David P. Holveck, president and CEO of Endo,
will review the company’s products and development programs.
The presentation will be webcast live and can be accessed from
Endo’s website at www.endo.com under the investors
section.
About Endo
Endo Pharmaceuticals is a U.S.-based, specialty healthcare
solutions company, focused on high-value branded products and
specialty generics. Endo is redefining its position in the
healthcare marketplace by anticipating and embracing the evolution
of health decisions based on the need for high-quality and
cost-effective care. We aim to be the premier partner to healthcare
professionals and payment providers, delivering an innovative suite
of complementary diagnostics, drugs, devices and clinical data to
meet the needs of patients in areas such as pain, urology, oncology
and endocrinology. For more information about Endo Pharmaceuticals,
and its wholly owned subsidiaries HealthTronics, Inc. and Qualitest
Pharmaceuticals, please visit www.endo.com.
‘/>”/>
SOURCE
